Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-7,896
Closed -$229K 94
2024
Q3
$229K Buy
+7,896
New +$230K 0.18% 84
2024
Q1
Sell
-7,391
Closed -$213K 94
2023
Q4
$213K Sell
7,391
-673
-8% -$20.3K 0.19% 80
2023
Q3
$267K Sell
8,064
-368
-4% -$13K 0.25% 64
2023
Q2
$309K Buy
8,432
+98
+1% +$3.81K 0.28% 63
2023
Q1
$340K Buy
8,334
+236
+3% +$10.2K 0.32% 55
2022
Q4
$415K Buy
8,098
+79
+1% +$3.79K 0.41% 46
2022
Q3
$351K Sell
8,019
-163
-2% -$7.92K 0.4% 47
2022
Q2
$429K Buy
8,182
+652
+9% +$33.2K 0.48% 45
2022
Q1
$390K Buy
7,530
+121
+2% +$6.28K 0.36% 53
2021
Q4
$438K Buy
+7,409
New +$367K 0.41% 44

Other funds holding PFE

Unionview LLC's PFE Position: Q4 2024 in Review

Unionview LLC sold out of Pfizer (PFE) in Q4 2024, closing a stake of 7,896 shares — an estimated $229K sold.

Unionview LLC first reported a position in PFE in Q4 2021 and held it in 10 quarters. The position peaked at $438K in Q4 2021. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Unionview LLC reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
  • Unionview LLC sold 7,896 Pfizer shares in Q4 2024, an estimated $229K.
  • Unionview LLC first reported a position in Pfizer in Q4 2021 and held it in 10 quarters.
  • Unionview LLC's Pfizer position peaked at $438K in Q4 2021.
  • 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Unionview LLC's 13F filing for Q4 2024, filed 3 Feb 2025.